Cholinesterase inhibitors and Alzheimer's disease

patient, carer and professional factors influencing the use of drugs for Alzheimer's disease in the United Kingdom

Deborah Hutchings, Alessandro Vanoli, Ian McKeith, Sue Brotherton, Paul McNamee, John Bond*

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Between 2001 and 2006 UK guidance recommended that people with mild to moderate Alzheimer's disease were eligible for treatment with donepezil, rivastigmine and galanatamine on the National Health Service (NHS). However, there was considerable variation in uptake of and access to treatment. This qualitative study aimed to understand which factors influence decisions to initiate, continue and discontinue treatment with the drugs. The views and experiences of 12 older people referred for memory problems or receiving treatment, 11 family carers and 16 health and social care professionals were obtained using a combination of semi-structured interviews and focus groups. Four factors outside UK guidance and prescribing budgets influence decisions to utilize the drug treatments, namely: perceptions of treatment availability and effectiveness; resource capacity; carer perceived benefits; and professional ethics. Unequal access to treatment and ethical concerns remain key issues.

Original languageEnglish
Pages (from-to)427-443
Number of pages17
JournalDementia: the international journal of social research and practice
Volume9
Issue number3
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Cholinesterase Inhibitors
dementia
Caregivers
Alzheimer Disease
drug
professional ethics
Pharmaceutical Preparations
health service
budget
Rivastigmine
Therapeutics
interview
health
Professional Ethics
resources
experience
Group
National Health Programs
Budgets
Focus Groups

Keywords

  • Alzheimer's disease
  • cholinesterase inhibitors
  • decision making
  • evidence-based health and social care
  • treatment

ASJC Scopus subject areas

  • History
  • Social Sciences(all)
  • Sociology and Political Science
  • Cognitive Neuroscience
  • Medicine(all)

Cite this

Cholinesterase inhibitors and Alzheimer's disease : patient, carer and professional factors influencing the use of drugs for Alzheimer's disease in the United Kingdom. / Hutchings, Deborah; Vanoli, Alessandro; McKeith, Ian; Brotherton, Sue; McNamee, Paul; Bond, John.

In: Dementia: the international journal of social research and practice, Vol. 9, No. 3, 08.2010, p. 427-443.

Research output: Contribution to journalArticle

@article{6c82d50764cb42b588138ae2e71285cd,
title = "Cholinesterase inhibitors and Alzheimer's disease: patient, carer and professional factors influencing the use of drugs for Alzheimer's disease in the United Kingdom",
abstract = "Between 2001 and 2006 UK guidance recommended that people with mild to moderate Alzheimer's disease were eligible for treatment with donepezil, rivastigmine and galanatamine on the National Health Service (NHS). However, there was considerable variation in uptake of and access to treatment. This qualitative study aimed to understand which factors influence decisions to initiate, continue and discontinue treatment with the drugs. The views and experiences of 12 older people referred for memory problems or receiving treatment, 11 family carers and 16 health and social care professionals were obtained using a combination of semi-structured interviews and focus groups. Four factors outside UK guidance and prescribing budgets influence decisions to utilize the drug treatments, namely: perceptions of treatment availability and effectiveness; resource capacity; carer perceived benefits; and professional ethics. Unequal access to treatment and ethical concerns remain key issues.",
keywords = "Alzheimer's disease, cholinesterase inhibitors, decision making, evidence-based health and social care, treatment",
author = "Deborah Hutchings and Alessandro Vanoli and Ian McKeith and Sue Brotherton and Paul McNamee and John Bond",
year = "2010",
month = "8",
doi = "10.1177/1471301210375340",
language = "English",
volume = "9",
pages = "427--443",
journal = "Dementia: the international journal of social research and practice",
issn = "1471-3012",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Cholinesterase inhibitors and Alzheimer's disease

T2 - patient, carer and professional factors influencing the use of drugs for Alzheimer's disease in the United Kingdom

AU - Hutchings, Deborah

AU - Vanoli, Alessandro

AU - McKeith, Ian

AU - Brotherton, Sue

AU - McNamee, Paul

AU - Bond, John

PY - 2010/8

Y1 - 2010/8

N2 - Between 2001 and 2006 UK guidance recommended that people with mild to moderate Alzheimer's disease were eligible for treatment with donepezil, rivastigmine and galanatamine on the National Health Service (NHS). However, there was considerable variation in uptake of and access to treatment. This qualitative study aimed to understand which factors influence decisions to initiate, continue and discontinue treatment with the drugs. The views and experiences of 12 older people referred for memory problems or receiving treatment, 11 family carers and 16 health and social care professionals were obtained using a combination of semi-structured interviews and focus groups. Four factors outside UK guidance and prescribing budgets influence decisions to utilize the drug treatments, namely: perceptions of treatment availability and effectiveness; resource capacity; carer perceived benefits; and professional ethics. Unequal access to treatment and ethical concerns remain key issues.

AB - Between 2001 and 2006 UK guidance recommended that people with mild to moderate Alzheimer's disease were eligible for treatment with donepezil, rivastigmine and galanatamine on the National Health Service (NHS). However, there was considerable variation in uptake of and access to treatment. This qualitative study aimed to understand which factors influence decisions to initiate, continue and discontinue treatment with the drugs. The views and experiences of 12 older people referred for memory problems or receiving treatment, 11 family carers and 16 health and social care professionals were obtained using a combination of semi-structured interviews and focus groups. Four factors outside UK guidance and prescribing budgets influence decisions to utilize the drug treatments, namely: perceptions of treatment availability and effectiveness; resource capacity; carer perceived benefits; and professional ethics. Unequal access to treatment and ethical concerns remain key issues.

KW - Alzheimer's disease

KW - cholinesterase inhibitors

KW - decision making

KW - evidence-based health and social care

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=77956080581&partnerID=8YFLogxK

U2 - 10.1177/1471301210375340

DO - 10.1177/1471301210375340

M3 - Article

VL - 9

SP - 427

EP - 443

JO - Dementia: the international journal of social research and practice

JF - Dementia: the international journal of social research and practice

SN - 1471-3012

IS - 3

ER -